tases. 2 The classical morphology of chordomas has characteristic vacuolated physalipherous cells in a myxofibrillary background separated into clusters/ lobules. 1, 3 Chordomas are differentiated from histologically similar tumors via immunological markers, which include S-100, EMA, CK-10 and 19, and most recently brachyury. 3, 4 Chordomas are extremely rare with an annual incidence of 0.0001% in the general population, with approximately 300 new patients diagnosed each year in the United States. 5 Chordomas are slow growing, locally aggressive, and typically found at the VIewPoINts PRS Global Open • 2014 skull base and sacrococcygeal region. Median age of presentation is reported to range from 59 to 62 years, with a gender predilection in sacrococcygeal chordomas for men of 2:1. 5 Clinical presentation is dependent on the location of the enlarging mass, with sacral tumors presenting with chronic lower back pain, lower extremity neurological deficits, and bowel/bladder dysfunction while intracranial tumors presenting with headache, diplopia, and craniofacial pain. Primary treatment for a chordoma is wide margin surgical excision. 1 Local recurrence rates greater than 70% have been reported in surgically treated chordomas with nonnegative margins, and although chordoma metastasis is rarely evident during initial diagnosis, it presents later in the disease process in 40-60% of patients. 1, 5 Common sites for metastasis include the lungs, liver, heart, lymph nodes, and vertebrae. 5 Metastatic chordomas present a significant diagnostic challenge due to the rarity of the primary tumor and the nonspecific presentation of the metastatic mass. This case illustrates the need for increased physician vigilance in monitoring newly identified masses in patients with a history of chordoma, by obtaining a biopsy and subsequent surgical excision of the metastatic mass. 
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